Last updated: February 14, 2026
Product Overview:
NDC 60505-2900 corresponds to a biosimilar product of the original biologic, Herceptin (trastuzumab). Biosimilars are drugs approved to produce the same therapeutic effects as their reference biologics, offering lower-cost alternatives.
Market Context:
Herceptin's sales have historically exceeded $6 billion annually worldwide, with the United States accounting for a significant share. The expiration of Herceptin's U.S. patent rights in 2019 has led to increased biosimilar market entry, including NDC 60505-2900. Biosimilar adoption impacts both revenue and pricing strategies of originator and biosimilar manufacturers.
Market Penetration and Competition:
- Several biosimilars for trastuzumab have launched, including counterparts from Mylan (Ogivri), Samsung Bioepis (Herzuma), and Pfizer (Trazimera).
- Market acceptance is driven by insurance formulary preferences, physician adoption, and competitive pricing.
- As of 2023, biosimilars capture approximately 30% of trastuzumab sales in the U.S., with ongoing increases.
Pricing Trends:
- The original Herceptin (NDC 00006-0476-02) averaged wholesale acquisition costs (WAC) of about $6,800 per 440 mg vial.
- Biosimilar prices have ranged from 15% to 25% below the originator, with discounts often between 20% and 30% once fully established in the market.
- Current WAC for NDC 60505-2900 approximates $4,950 to $5,400 per 440 mg vial, reflecting a 20-25% discount relative to the originator.
| Price Projections (2023-2027): |
Year |
Estimated WAC per 440 mg vial |
Key Assumptions |
| 2023 |
$5,000 - $5,400 |
Market fully launched; biosimilar gains acceptance |
| 2024 |
$4,850 - $5,200 |
Increased competition and payer negotiations |
| 2025 |
$4,700 - $5,050 |
Price stabilization as biosimilar market matures |
| 2026 |
$4,600 - $4,950 |
Marginal discounts; possible new entrants or biosimilar updates |
| 2027 |
$4,500 - $4,850 |
Market saturation; price plateau possible |
Key Factors Influencing Price Trends:
- Regulatory developments and new biosimilar approvals.
- Payer and formulary decisions favoring biosimilars.
- Manufacturing and supply chain efficiencies.
- Patent litigation and legal disputes affecting market entry.
Revenue Impact:
- Biosimilar market share could surpass 50% by 2027, reducing overall trastuzumab revenue.
- The biosimilar's lower price point increases access, but limits the revenue per unit for manufacturer.
Regulatory and Policy Landscape:
- The FDA has approved multiple trastuzumab biosimilars since 2017, with ongoing approval of next-generation versions.
- CMS policies increasingly favor biosimilars through reimbursement structures favoring lower-cost options.
- Biosimilar adoption varies across payors and providers, influencing market prices.
Market Opportunities and Risks:
- Opportunities include expanding indications, developing combination therapies, and entering emerging markets.
- Risks involve patent litigations, slow physician adoption, and payer resistance to switching from originator biologics.
Conclusion:
NDC 60505-2900's market movement aligns with biosimilar trends observed globally. Price projections show potential for further reductions driven by competitive dynamics. Continued market penetration depends on regulatory environment, payer policies, and physician acceptance.
Key Takeaways
- Prices for NDC 60505-2900 are expected to remain in the $4,500-$5,400 range through 2027.
- Biosimilar competition has driven down costs relative to the originator Herceptin.
- Market share growth among biosimilars will influence revenue and future pricing.
- Regulatory and policy environments are pivotal in shaping market dynamics.
- Manufacturers must navigate legal, operational, and market challenges to sustain positioning.
FAQs
1. How does biosimilar pricing compare to the original biologic?
Biosimilars are typically priced 15-30% lower than the reference biologic, with current WACs for NDC 60505-2900 around 20% below Herceptin's origination price.
2. What factors are driving biosimilar market growth?
Market growth is driven by patent expirations, clinician acceptance, insurance formulary preferences, and policy incentives favoring lower-cost biologics.
3. What are the primary legal considerations impacting biosimilar prices?
Patent litigations, settlement agreements, and legal disputes can delay biosimilar market entry or influence pricing strategies.
4. How might policy changes affect biosimilar prices?
Policies promoting biosimilar substitution and reduced reimbursement for originators can further lower biosimilar prices.
5. What is the outlook for biosimilar adoption beyond 2025?
Adoption is expected to increase as stakeholders become more familiar with biosimilars, and as regulatory pathways simplify the approval process in various regions.
Sources:
[1] IQVIA, "Biologic and Biosimilar Market Trends", 2022.
[2] FDA, "Biosimilar Approval and Regulatory Framework", 2023.
[3] SSR Health, "US Biosimilar Market Data", 2023.
